Bridge­Bio adds 3 more in­sti­tu­tions to its ros­ter of col­lab­o­ra­tors; Ex­sci­en­tia lands Gates Foun­da­tion mon­ey for Covid-19 pill 

Bridge­Bio chief Neil Ku­mar is adding to his long list of re­search part­ners.

The biotech CEO an­nounced this morn­ing that the com­pa­ny’s hunt for new drugs to treat ge­net­ic dis­eases and can­cers with clear ge­net­ic dri­vers has sparked new al­liances with re­searchers at Stan­ford, MUSC Foun­da­tion for Re­search De­vel­op­ment and the Uni­ver­si­ty of Pitts­burgh.

Bridge­Bio — which em­ploys a hub and spoke com­pa­ny struc­ture — counts 23 in­sti­tu­tions on its list of col­lab­o­ra­tors. That ap­pears to be a work in progress, with more on the way. — John Car­roll

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER